<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Standard treatment for transplant-eligible patients with relapsed diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) consists of rituximab and <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based chemotherapy, either ifosfamide, <z:chebi fb="2" ids="31355">carboplatin</z:chebi>, and <z:chebi fb="0" ids="4911">etoposide</z:chebi> (ICE) or <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and <z:chebi fb="2" ids="27899">cisplatin</z:chebi> (<z:chebi fb="0" ids="16108">DHAP</z:chebi>), with autologous transplant consolidation for those with chemosensitive disease </plain></SENT>
<SENT sid="1" pm="."><plain>Nonetheless, outcomes are suboptimal for patients failing rituximab, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (R-CHOP) </plain></SENT>
<SENT sid="2" pm="."><plain>We performed a multi-center phase II trial investigating the safety and efficacy of ofatumumab (O), a monoclonal antibody against CD20, combined with ICE or <z:chebi fb="0" ids="16108">DHAP</z:chebi> second-line therapy in patients with relapsed or refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, grade 3b follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), or transformed FL </plain></SENT>
<SENT sid="3" pm="."><plain>Sixty-one patients were treated with either O-ICE (35) or O-<z:chebi fb="0" ids="16108">DHAP</z:chebi> (26) </plain></SENT>
<SENT sid="4" pm="."><plain>The overall response rate (ORR) was 61%, and the complete response (CR) rate was 37% </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with two or three adverse risk factors according to the second-line age-adjusted international prognostic index, ORR was 59% and CR 31%, and in patients with early-relapsing or primary refractory disease, ORR was 55% and CR 30% </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity was largely hematologic, and stem cell mobilization was successful in 43 of 45 patients </plain></SENT>
<SENT sid="7" pm="."><plain>Substitution of ofatumumab for rituximab in standard second-line regimens following failure of R-CHOP is a promising approach </plain></SENT>
<SENT sid="8" pm="."><plain>This trial was registered at www.clinicaltrials.gov as NCT00823719 </plain></SENT>
</text></document>